ArticleIJTLD open2026
Can we optimise the TB response amid funding constraints using evidence-based, cost-effective strategies.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite progress in the TB response, including through the Global Fund's catalytic efforts, funding gaps and inefficiencies threaten efforts to sustain gains and accelerate the TB response. Recent donor funding cuts have further strained programmes in low- and middle-income countries.
methodsA mixed-method, combining desk and literature review and key informant interviews with national TB programme stakeholders, technical experts, and partners, was conducted using standardised tools. Findings were triangulated to identify strategies/approaches that improve efficiency, access, and outcomes.
resultsWe identified cost-effective strategies that optimise resources and tools to sustain and expand access to services amid declining funding. Strategies to enhance efficiency include screening using digital X-rays (with artificial intelligence), testing samples (including pooled samples) with molecular diagnostics, decentralising care, engaging communities and private sector, and integrating TB services with broader health system. Cost-saving measures involve integrated sample transport and supervision, integrating TB with other diseases such as HIV, diabetes, and undernutrition, task shifting, shorter treatment regimens, digital tools, and e-learning. Emphasis was also placed on innovative financing, domestic resource mobilisation, and country ownership.
conclusionAccelerating to end TB requires integrated and efficient strategies, innovative financing, and increased domestic resources, ensuring provision of equitable and high-quality TB services while strengthening the health system and ensuring sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.